Clinical Trials Directory

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) or HEARTLIGHT for the Treatment of Symptomatic Atrial Fibrillation

The purpose of this study is to demonstrate the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact (HeartLight) in the treatment of atrial fibrillation by creating electrical isolation of the pulmonary veins.

Stanford is now accepting new patients for this trial. Please contact Linda Norton, RN at 650-725-5597 for more information.



  • device : EAS-AC (HeartLight)
  • procedure : Control Arm Ablation

Phase: Phase 3


Ages Eligible For Study:

18 Years - 75 Years

Inclusion Criteria

- 18 to 75 years. - paroxysmal atrial fibrillation - failure of at least one AAD - others

External Links

Explore related trials

Contact information

Primary Contact:

Linda Norton, RN 650-725-5597

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: